An update on APC I1307K homozygosity: observations from a large multigene panel testing cohort

Leah Zaretsky, Marcy E Richardson, Taylor Coleman, Carrie Horton, Magan Trottier, Maggie Feng, Linda M Polfus, Aimee L Lucas · 2026

Read An update on APC I1307K homozygosity: observations from a large multigene panel testing cohort by Leah Zaretsky, Marcy E Richardson, Taylor Coleman, Carrie Horton, Magan Trottier, Maggie Feng, Linda M Polfus, Aimee L Lucas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585870.txt.

Introduction

Leah Zaretsky and co-authors size up colon cancer risk for people carrying two copies of a gene variant in a 2026 study. One copy of the APC I1307K variant, common in Ashkenazi Jewish ancestry, is known to raise risk modestly. What two copies do was unclear from small samples.

In a large testing cohort, seventy four double carriers showed a trend toward higher colon cancer odds than variant free patients, while single carriers showed none. A comparison group with a classic inherited syndrome ran higher still in raw terms, though adjusted math blurred that gap. The authors caution that sample size and testing bias limit firm numbers, and the true risk may be modest or nil.

Catalog record

CREATORLeah Zaretsky, Marcy E Richardson, Taylor Coleman, Carrie Horton, Magan Trottier, Maggie Feng, Linda M Polfus, Aimee L Lucas
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13585870

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

An update on APC I1307K homozygosity: observations from a large multigene panel testing cohort Authors: Leah Zaretsky, Marcy E Richardson, Taylor Coleman, Carrie Horton, Magan Trottier, Maggie Feng, Linda M Polfus, Aimee L Lucas Published: 2026 ABSTRACT AbstractNumerous studies have demonstrated that Ashkenazi Jewish individuals heterozygous for APC c.3902T > A; p.Ile1307Lys have 1.7-fold increased odds of colorectal adenocarcinoma (CRC). The cancer risk for homozygotes is unknown, and published data is based on small sample sizes. Here, we aim to quantitatively evaluate the odds of CRC in homozygotes from a clinical diagnostic setting. Analyses comparing the demographic and clinical histories among heterozygotes (n = 340) or homozygotes (n = 74) were compared to individuals with MSH6-associated Lynch syndrome (n = 372) and individuals from a pan-cancer panel of up to 90 genes who were negative for APC I1307K, MSH6 (likely) pathogenic (LP/P) variants, and other reportable LP/P variants after exclusions, henceforth referred to as wildtype (WT, n = 19,809). Comparisons included Fisher’s exact or two-sample t-test and multivariate logistic regression. Homozygotes demonstrated a trend toward increased odds of CRC compared to WT (OR: 2.48; p = 0.074), and there was no difference between heterozygotes and WT (OR: 0.94; p = 0.83). MSH6-positive individuals had increased odds of CRC relative to homozygotes (OR: 3.54; p < 0.0001) but this was not significant in the logistic regression (OR: 1.19; p = 0.78). While homozygotes but not heterozygotes demonstrated an increase in CRC OR compared to WT, there was no statistically distinct odds of CRC between heterozygotes and homozygotes in this cohort. While the ORs herein support that the observed increase in CRC for homozygotes was more modest than that observed for MSH6-related Lynch syndrome in this cohort, current sample size and selection bias limit precise risk estimation and do not allow for distinction between modestly increased risk and no risk of CRC.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s10689-026-00600-0.Keywords: APC, Homozygote, p.I1307K, p.Ile1307Lys, Colon cancer risk Introduction Colorectal adenocarcinoma (CRC) is a leading cause of cancer-related morbidity and mortality worldwide [1]. Genetic predisposition plays a crucial role in the development of CRC, with several (likely) pathogenic (LP/P) variants identified as significant contributors to the onset of disease. One such variant, APC (NM_000038.6) c.3902T > A p.Ile1307K (I1307K), is known to generate an unstable tract of eight adenines which creates a hypermutable region of the gene and has been linked to an increased risk of CRC, albeit lower than other APC LP/P variants [2, 3]. Further research is needed to better understand the risks associated with APC I1307K [4], as the impact of this genetic variant in various populations, including its effect on homozygotes, remains inadequately explored [5]. The APC I1307K variant is found in the Ashkenazi Jewish (AJ) population with a frequency nearing 4% (gnomAD v.4.1.1). Several studies have indicated a lifetime CRC risk of 5–10% in APC I1307K heterozygotes in AJ populations [6, 7]. Other studies have similarly shown increases in CRC risk in smaller cohort and case series [2], further reinforcing the association between APC I1307K and increased CRC susceptibility. Based on these estimates of increased risk, the National Comprehensive Cancer Network (NCCN) currently recommends that APC I1307K heterozygotes receive CRC screening with colonoscopy every five years beginning at age 40 [8], in contrast to average-risk individuals, for whom colonoscopy is recommended every 10 years beginning at age 45 or 50, or for whom alternative screening strategies, including stool-based screening, may be used [9, 10]. The Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (VCEP), in conducting reviews of APC variants, stated that variant interpretation guideline criteria cannot be applied to frequent/low penetrant variants in APC, including I1307K, as the clinical presentation and disease mechanism of these variants are heterogeneous and complex [11]. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) currently does not recommend early screening in APC I1307K heterozygotes [4]. Despite the prevalence of the APC I1307K variant in individuals of AJ descent, the incidence of homozygotes is rare [6], and the mechanism of disease for this variant in this context remains poorly understood. The largest case series of homozygous individuals published to-date includes only four individuals, and these and other homozygous individuals reported in the literature exhibited wide phenotypic variability [12, 13]. In this report, a large cohort of individuals homozygous for APC I1307K was evaluated and compared to heterozygotes as well as positive (MSH6+) and negative (WT) control cohorts. The primary objective of this brief report is to quantitatively evaluate the CRC OR in APC I1307K homozygotes ascertained from a clinical diagnostic setting. Methods Study design and population The primary objective of this study is to assess the OR of CRC in APC I1307K homozygotes. Additionally, we aim to describe the clinical characteristics and phenotypic expression of APC I1307K homozygous individuals. In this retrospective cohort study, de-identified data from individuals who underwent multigene panel testing for hereditary cancer indications were evaluated. Individuals underwent a multigene panel test (up to 90 genes) [14] between May 2012 and April 2024 at a single diagnostic testing laboratory (Ambry Genetics, Aliso Viejo, CA). Statistical models used WT and MSH6-positives as negative and positive control cohorts, respectively. For APC I1307K homozygotes, all available cases were clinically curated. For APC I1307K heterozygotes, MSH6-positives, and WT cohorts, only select individuals had been curated for a variety of reasons including billing purposes, resulting in curation that is nearly random. There was a small proportion of individuals who were curated based on genotype- and/or phenotype-related projects; however, these are a minority of cases and are expected to be diverse enough so as not to strongly sway the data. Individuals heterozygous for LP/P variants in MSH6 were included as a comparison group, given this gene’s well-established cancer risks and management recommendations, which are considered to be at the relatively lower end of the spectrum among Lynch syndrome susceptibility genes. MSH6 heterozygotes are generally recommended to have colonoscopies every one to three years beginning at age 30 to 35 due to a cumulative risk for CRC through age 70 of around 12% [15]. The WGC IRB (formerly the Western Institutional Review Board) determined that the study was exempt from the Office for Human Research Protection Regulations for the Protection of Human Subjects (45 CFR 46) and provided a waiver of consent for Ambry de-identified data analyzed collectively. Clinical characteristics were obtained from clinician-completed test requisition forms and supplemented with clinical documentation, including pedigrees and clinical notes, when available. The clinical and demographic characteristics included age at testing, age at diagnosis (if available), sex at birth, self-reported ethnicity, immunohistochemistry (IHC) status, and microsatellite instability levels. Reportable variants included variants of uncertain significance (VUS) and LP/P variants as determined by laboratory-specific guidelines modified from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) [16]. Patients were excluded from analyses if they had co-occurring LP/P variants in any gene on the ordered cancer panel. Co-occurring VUSs were allowed for all cohorts, as most VUSs that are reclassified are downgraded to benign. The WT cohort was negative for APC I1307K, MSH6 LP/P variants, and other reportable LP/P variants after exclusions. Additional exclusion criteria for the APC I1307K heterozygote/homozygote and WT cohorts included those

Read the complete text